Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 4/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459850 | 0.86 | EPHX2 (0.52) | PARP1POLBRIPK1CCR3EPHX2 | |
| SCHEMBL459399 | 0.85 | CCR3 (0.40) | POLBCCR3HRH1CCNT1CDK9 | |
| SCHEMBL459909 | 0.83 | CCR3 (0.40) | CCR3HRH1 | |
| SCHEMBL460370 | 0.81 | CCR3 (0.51) | CCR3EPHX2 | |
| SCHEMBL459347 | 0.81 | ALDH1A1 (0.45) | POLBCCR3ALDH1A1EPHX2 | |
| SCHEMBL459356 | 0.81 | CCR3 (0.53) | CCR3MGLLEPHX2 | |
| SCHEMBL460548 | 0.81 | EPHX2 (0.53) | CCR3MGLLALDH1A1EPHX2 | |
| SCHEMBL460513 | 0.80 | HPGDS (0.44) | ALDH1A1 | |
| SCHEMBL457742 | 0.79 | ALDH1A1 (0.46) | POLBCCR3ALDH1A1EPHX2 | |
| SCHEMBL458157 | 0.79 | EPHX2 (0.43) | POLBCCR3ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | claimed |
| EP-2615084-B1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9181183-B2 | Prostaglandin D synthase inhibitory piperidine compounds | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2615084-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | US | disclosed |
| WO-2012033069-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | 大鵬薬品工業株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165438-A1 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS | PTGIS, PTGS1, PTGDR | PARP1 912/4885POLB 574/4885RIPK1 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.